Manufacture of Sterile Medicinal Products
Revised Annex 1 introduces the mandatory Contamination Control Strategy (CCS) as a holistic document integrating all contamination prevention measures across site, facility, equipment, personnel, and processes. It is among the most comprehensive revisions in the document's history.
What this does not cover
stated in the document's own scope- Covers sterile medicinal products; general non-sterile GMP is the subject of the main chapters of the EU GMP Guide, not Annex 1.
- Sets manufacturing GMP for sterile products, not the qualification and validation methodology itself, which is Annex 15.
- Addresses contamination control and sterility assurance, not computerised-system controls, which are covered by Annex 11.
- Applies to the making of the product, not its distribution once released, which falls under the EU GDP guidelines.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
EU GMP Annex 1, "Manufacture of Sterile Medicinal Products", is the guidance that governs how sterile human and veterinary medicines are made — covering cleanroom classification and qualification, barrier technologies such as isolators and RABS, HVAC and pressure regimes, personnel gowning and behaviour, aseptic process simulation, water and gas systems, sterilisation, and the release of the finished product. The 2022 revision was the most extensive rewrite in the annex’s history: it more than doubled in length, adopted quality-risk-management and contamination-control thinking throughout, and requires the manufacturer to hold a facility-wide Contamination Control Strategy (CCS) that draws the individual controls into one documented, evaluated whole.
Scope & applicability
All manufacturers of sterile medicinal products for human and veterinary use operating under EU GMP. Also adopted by PIC/S member states globally.
Legal basis & how it acquires force
Annex 1 is part of Volume 4 of EudraLex, the EU GMP Guide, which gives detailed guidance on the GMP principles that Directive 2003/94/EC (human medicines) and the corresponding veterinary provisions require manufacturers to observe. As an annex it is interpretive guidance rather than free-standing statute, but compliance is a condition of the manufacturing authorisation, so it carries practical binding force in the EU/EEA. The 2022 version was published jointly by the European Commission, EMA and PIC/S; it became effective on 25 August 2023, with the lyophilisation provisions of point 8.123 applying from 25 August 2024.
Document structure
| Part | Covers |
|---|---|
| Scope and Principle | Products and processes covered, and the overarching contamination-control and QRM philosophy |
| Pharmaceutical Quality System / Contamination Control Strategy | The requirement for a documented, facility-wide CCS integrating all contamination-prevention measures |
| Premises and Equipment | Cleanroom grades A–D, barrier systems, HVAC, and utility design |
| Personnel and Production Technologies | Gowning, training, aseptic processing, form-fill-seal, lyophilisation, and closed systems |
| Environmental and Process Monitoring | Viable and non-viable monitoring, aseptic process simulation, and trending |
| Quality Control and Sterilisation | Sterilisation methods, sterility assurance, and finished-product controls |
Key requirements
- Contamination Control Strategy (CCS) as a site-level document linking all contamination controls
- RABS or isolator technology for all new sterile manufacturing facilities
- Documented justification for any Grade A area that does not use a barrier system
- Glove integrity testing — frequency and methods must be documented in CCS
- Environmental monitoring trending with defined alert/action levels and investigation procedures
- Personnel monitoring at specific anatomical sites with frequency based on risk
- Media fill programme covering all operators, shifts, and critical interventions
Implementation tips
- CCS structure should mirror Annex 1 section headings — makes inspection much faster
- Gap assessment against Annex 1 2022 vs. 2003 should be documented — inspectors ask what changed
- Glove integrity testing policy needs to define: pre-use, post-use, routine, and frequency justification
- Start with your highest-risk Grade A operations when prioritising CCS documentation
Revision notes
August 2022 full revision replacing 2003 version. Major changes: mandatory CCS, barrier technology preference, glove integrity, expanded environmental monitoring requirements, new media fill requirements.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Annex 1 was revised as a joint EU–PIC/S project, so PIC/S adopted the same text (PE 009 Annex 1) and the two are effectively identical worldwide. It sits within the wider ICH quality framework, reflecting ICH Q9 on quality risk management and Q10 on the pharmaceutical quality system, and it references cleanroom-classification principles aligned with ISO 14644. It is the EU counterpart to the sterile-drug expectations FDA sets through its aseptic-processing guidance.
EU GMP Annex 1 (2022): frequently asked questions
Quick answers to common questions about EU GMP Annex 1 (2022).
When did the 2022 revision of EU GMP Annex 1 become effective?
The revised Annex 1 came into effect on 25 August 2023. One provision — point 8.123 on lyophilisation — was given an additional year and applied from 25 August 2024.
What is the Contamination Control Strategy in Annex 1?
The 2022 revision requires manufacturers to hold a facility-wide Contamination Control Strategy: a single document that defines all the controls in place for microbial, particulate and endotoxin contamination across site, facility, equipment, personnel and process, and shows how they work together rather than listing them in isolation.
Is EU GMP Annex 1 the same as the PIC/S sterile-products annex?
Yes. The 2022 revision was a joint EU–PIC/S project, so PIC/S issued the identical text as its own Annex 1. A manufacturer meeting the EU version meets the PIC/S version.
Does Annex 1 apply to non-sterile products?
No. Annex 1 is specific to sterile medicinal products. Non-sterile manufacture is governed by the general chapters of the EU GMP Guide and the other annexes that apply to the process in question.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.